SUMMARY. Platelet-activating factor is a novel phospholipid that has been implicated as an important mediator of acute allergic reactions. The intravenous administration of acetyl glyceryl ether phosphorylcholine, a pure, synthetic platelet-activating factor, causes electrocardiographic changes in the rabbit similar to those which are characteristic manifestations of systemic anaphylaxis. To determine whether platelet-activating factor contributes to anaphylactic cardiac dysfunction, we measured platelet-activating factor release from the sensitized guinea pig heart challenged in vitro with specific antigen and compared the resulting cardiac dysfunction with that induced by the injection of acetyl glyceryl ether phosphorylcholine into nonsensitized hearts. The results of these studies document that, during anaphylaxis in the isolated guinea pig heart, a plateletactivating factor is released into the coronary effluent that has physicochemical and functional properties similar to those of acetyl glyceryl ether phosphorylcholine. The intracardiac administration of acetyl glyceryl ether phosphorylcholine (10~1 4 to 3 X 10" 9 mol) induced dose-related decreases in left ventricular contractile force (-5 to -85%) and coronary flow (-5 to -85%), as well as impaired a trio ventricular conduction. The negative inotropic effect of acetyl glyceryl ether phosphorylcholine also was present in hearts perfused at constant flow. Although, in these hearts, acetyl glyceryl ether phosphorylcholine increased coronary resistance, which may have caused regional shunting and ischemia, it is unlikely that the negative inotropic effect of acetyl glyceryl ether phosphorylcholine was secondary to changes in coronary flow, since acetyl glyceryl ether phosphorylcholine also caused a dose-dependent negative inotropic effect in the electrically paced, noncoronary-perfused left atrium and right ventricular papillary muscle. Moreover, the cardiac effects of acetyl glyceryl ether phosphorylcholine were not modified by indomethacin or FPL 55712, indicating that they were not mediated by various cyclooxygenase or lipoxygenase products of the arachidonic acid cascade. These data suggest that platelet-activating factor may contribute to the contractile failure, reduced coronary flow, and conduction arrhythmias of cardiac anaphylaxis. (Circ Res 54:117-124, 1984) 
PLATELET-activating factor (PAF) has been implicated as an important mediator of immediate hypersensitivity (ci. Pinckard et al., 1982) . During systemic anaphylaxis in the rabbit, PAF release is associated with intravascular platelet alterations that are consistent with the platelet-stimulating activities of purified PAF in vitro (Halonen and Pinckard, 1975; Henson and Pinckard, 1977; Pinckard et al., 1977 Pinckard et al., , 1979 McManus et al., 1979) . Following the structural elucidation of rabbit basophil-derived PAF as acetyl glyceryl ether phosphorylcholine [1-O-hexadecyl / octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AGEPC) (Demopoulos et al., 1979; Hanahan et al., 1980) ], it was shown that the intravenous administration of AGEPC reproduced all the pathophysiological sequelae of IgE-induced systemic anaphylaxis in the rabbit Halonen et al., 1980) . In addition, AGEPC has been shown to possess an impressive array of biological activities, some of which are similar to those of other mediators of acute allergic reactions, e.g., vasoactivity and the ability to contract guinea pig ileum and parenchymal lung strips (c.f. Pinckard et al., 1982) . These findings suggest that, in addition to its potent platelet-activating properties, AGEPC may play a major role in mediating the pathophysiological changes of systemic anaphylaxis.
The possibility that AGEPC may also mediate cardiac abnormalities that occur during systemic anaphylaxis was first suggested by the finding that the intravenous infusion of AGEPC in the rabbit caused electrocardiographic changes which are typically encountered during acute allergic reactions [e.g., rightward shifts in the QRS axis, ischemic S-T segment changes, and brady-and tachyarrhythmias (Pinckard et al., unpublished observations) ]. Since
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Circulation Research/Vol. 54, No. 2, February 1984 these changes could have been secondary to pulmonary hypertension, systemic hypotension, and reduced cardiac output (Halonen et al., 1980) , a model of anaphylaxis was required in which cardiac dysfunction could be studied independently of systemic vascular and platelet-mediated changes. The isolated, sensitized guinea pig heart provided such a model. Indeed, many of the cardiac abnormalities characteristic of systemic anaphylaxis are manifested in vitro when hearts from sensitized guinea pigs are challenged with specific antigen ["cardiac anaphylaxis* (Feigen et al., 1961) ]. Sinus tachycardia, arrhythmias, decreased coronary flow, and left ventricular contractile failure are characteristic of cardiac anaphylaxis (Capurro and Levi, 1975) . Concurrently, endogenous substances known to mediate systemic anaphylaxis are released intracardially; these substances include histamine, and a number of arachidonic acid metabolites Levi et al., 1982) .
The objective of the present study, therefore, was to determine whether PAF might contribute to anaphylactic cardiac dysfunction. To this end, we measured the release of PAP from isolated sensitized guinea pig hearts during anaphylaxis, we assessed the physiological effects of exogenously administered AGEPC on the isolated nonsensitized guinea pig heart, and we compared these effects with the cardiac dysfunction observed during anaphylaxis.
Methods

Cardiac Anaphylaxis
Male Hartley guinea pigs (250-300 g) were passively sensitized by intravenous injection of 0.4 mg of guinea pig anti-dinitrophenyl-bovine-7-globulin IgGi (anti-DNP-BGG) (Levi and Burke, 1980) . This dose of anti-DNP-BGG was shown by the method of Ovary (1964) to be 2000 PCA units. Twelve hours after sensitization, the animals were killed by cervical dislocation, and the hearts were excised and mounted in a Langendorff apparatus (Levi and Burke, 1980) . The hearts were perfused at a constant pressure of 40 cm of water with Ringer's solution warmed to 37°C and equilibrated with oxygen. This solution contained (mM): Na + , 160; K + , 5.6; Ca ++ , 2.2; Cl", 164; HCO 3~, 5.9; glucose, 5.5; and human serum albumin (HSA; New York Blood Center), 2.5 mg/ml. Isometric ventricular contractions and bipolar surface electrograms were continuously recorded from the right atrium and left ventricle, as previously described (Levi and Burke, 1980) . Coronary flow rate was continuously monitored by measuring the volume of coronary effluent collected during 2-minute periods.
After a period of stabilization (30-45 minutes), the hearts from sensitized animals were challenged intraaortically with specific antigen [1 mg of DNP-bovine serum albumin (DNP-BSA)]. The 2-minute samples of coronary effluent were assayed for histamine and PAF. Histamine was measured by a radioenzymatic method (Beaven et al., 1982) , and highly purified PAF was assayed as described below.
Response of Isolated Hearts to Exogenous AGEPC
Hearts from nonsensitized male Hartley guinea pigs were mounted in the Langendorff apparatus and perfused at 37°C, either at constant pressure, as described above, or at constant flow. Under constant flow, Krebs-Henseleit solution continuously aerated with 95% O 2 /5% CO 2 was perfused through the heart. The composition of the KrebsHenseleit solution was (mM): Na + , 142.5; K + , 5.4; Ca ++ , 2.5; Mg-1 -, 1.2; Cl", 128; HCCV, 24.9; H 2 PCV, 1.0; SO 4 ", 1.2; glucose, 11.1; and HSA, 2.5 mg/ml. The solution was delivered by a peristaltic pump (Buchler Instruments, Polystaltic pump). The flow rate was adjusted to give a control perfusion pressure of 40 mm of Hg. The perfusion pressure was continuously monitored with a physiological pressure transducer (Statham model P23AA). Under both conditions, isometric ventricular contraction and bipolar surface electrogram were recorded as noted above.
AGEPC (1 -O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl3-phosphorylcholine) and lyso-GEPC (1-O-hexadecyl/ oyl-sn-glyceryl-3-phosphorylcholine) v^ were w synthesized, purified, and structurally characterized, as described previously (Demopoulos et al., 1979) . Under constant pressure conditions, a single dose of AGEPC (10~1 4 to 3 X 10" 9 mol) or its deacetylated derivative, lyso-GEPC (lO" 9 to 10~8 mol), dissolved in a constant volume of warm oxygenated Ringer's containing 2.5 mg/ml HSA, was injected intraaortically to determine dose-response relationships. To avoid the possibility of tachyphylaxis, only one dose of AGEPC was administered to each heart. Under constant flow conditions, AGEPC (10~1 2 to 10" 8 M in Krebs-Henseleit solution) was continuously perfused through the heart. The hearts were exposed to each concentration to AGEPC for 10 minutes, followed in turn by the next higher concentration.
In some experiments, AGEPC also was administered to the hearts in the presence of indomethacin or compound FPL 55712. In these studies, indomethacin (Sigma Chemical Co.) (1 Mg/ml in Ringer's solution) or FPL 55712 (donated by Fisons Pharmaceuticals, U.K.) (250 ng/ml in Ringer's solution) was continuously perfused through the heart from 30 minutes before AGEPC administration to the end of the experiment. This concentration of indomethacin had been previously documented by us to abolish the synthesis of cyclooxygenase products during cardiac anaphylaxis (Allan and Levi, 1981) . The concentration of FPL 55712 used here had been shown by us to shift the dose-response curves for the negative inotiopic and coronary-constricting effects of leukotrienes C< and D 4 in the guinea pig heart to the right by one to two log units (Burke et al., 1982a) .
Responses of Left Atria and Right Ventricular Papillary Muscles to AGEPC
The left atrium and right ventricular papillary muscle were isolated from guinea pig hearts, as previously described (Burke et al., 1982a) . Left atria and papillary muscles were mounted vertically in double-walled Pyrex chambers (2.5 ml volume) and perfused at 30°C with Tyrode's solution, containing 2.5 mg/ml HSA, aerated with 95% O 2 -5% CO 2 . The composition of the Tyrode's solution was (mM): Na + , 149.42; K + , 5.4; Cl", 148.1; Mg-, 1.05; Ca" 1 -, 1.8; HCCV, 12; H 2 PCV, 0.42; glucose, 10. Changes in tension were measured with a force-displacement transducer (model FTO3; Grass Instruments). Left atria and papillary muscles were paced with square pulses (duration, 5 and 10 msec for the left atrium and papillary muscle, respectively; voltage 1.5 times threshold) at a frequency of 1 and 2 Hz, respectively, with a pair of platinum electrodes placed in direct contact with the tissue and connected to a stimulator via a stimulus isolation unit Levi et u/./AGEPC and Cardiac Anaphylaxis (models S48 and S1U5, Grass Instruments). AGEPC or lyso-GEPC was added sequentially to the bath containing either the left atrium or the papillary muscle. Each dose was added after the change in contractility caused by the previous dose of AGEPC had reached a steady state level.
Purification, Bioassay, and Characterization of Cardiac Platelet-Activating Factor PAF activity was assessed by the ability of samples to stimulate [ 3 H]serotonin release from washed rabbit platelets (Table 1) , as previously described (Demopoulos et al., 1979) . PAF was estimated by referring to a standard curve constructed using known concentrations of AGEPC (Pinckard et al., 1982) . This method of evaluation is based on the assumption that guinea pig cardiac PAF and AGEPC are chemically identical. PAF activity also was assessed qualitatively by the more sensitive, but less quantitative, procedure of platelet aggregation; these PAF assays were conducted in the presence of 10 HM indomethacin and creatine kinase/creatine phosphate, as previously described .
Initial experiments were performed using three hearts obtained from guinea pigs passively sensitized with 3.3 mg rabbit anti-ovalbumin IgG (Levi, 1972) and three hearts passively sensitized with guinea pig anti-DNP IgGi antibody (described above). In these studies, no PAF activity was detected in the crude coronary effluents after antigen challenge. Therefore, the coronary effluent samples, which were obtained prior to and up to 10 minutes after antigen challenge, were extracted and purified by methods previously shown to be necessary for the recovery of PAF from biological samples Hanahan et al., 1980) . For this lipid extraction, one volume of chloroform (CHC1 3 ) and two volumes of methanol were added to each 0.8 volume of crude effluent. After 1 hour of incubation at room temperature, the precipitated proteins were removed by centrifugation and one volume each of CHC1 3 and water was added to the supernatant to effect phase separation. The lower, CHCb-rich phase then was subjected to thin layer chromatography (TLC) on precoated 250-^m Silica Gel G plates (Analtech), using a solvent system of CHCl 3 :methanol:water 65:35:6, vol/ vol/vol. Subsequently, each lane was sectioned into 1-cm segments starting at the origin, and the lipid in each fraction was extracted as described above. The CHCU-rich phase was evaporated to dryness prior to dissolution in saline containing 0.25% bovine serum albumin (BSA) for biossay. (Demopolous et al., 1979) . f Mean ± SEM; n = 7. Cardiac PAF was obtained from three anti-ovalbumin and four anti-DNP-sensitized hearts. The range of [ 3 H]serotonin secretion was 39.8-60.2% and 5.1-8.8% in control and AGEPC-desensitized platelets, respectively.
In contrast to the crude (unextracted) coronary effluents, PAF activity was detectable in the lipid-exrracted, TLC-purified samples obtained 2-10 minutes after antigen challenge of all six, sensitized hearts. No PAF was detected in the samples obtained prior to antigen challenge. Similarly, there was no detectable PAF in the samples from nonsensitized hearts challenged with antigen. Cardiac PAF activity detected by both platelet aggregation and [ 3 H]serotonin secretion was present only in TLC fractions with an R f = 0.20-0.24 and which co-migrated with AGEPC. Additional TLC purification revealed that the cardiac PAF also co-migrated with AGEPC utilizing a solvent system of methanohwater, 2:1, vol/vol, R f = 0.45-0.50. Subjecting this highly purified cardiac PAF, obtained from either anti-ovalbumin or anti-DNP-sensitized hearts, to base-catalyzed methanolysis (Demopoulos et al., 1979) destroyed all platelet-stimulating activity. Most important, platelets specifically desensitized to AGEPC did not respond to the purified cardiac PAF (see Table 1 ; Demopoulos et al., 1979) . Therefore, these studies demonstrated that a PAF is released during in vitro cardiac anaphylaxis in the guinea pig which possesses physicochemical and functional properties similar to those of AGEPC. The total amount of PAF released from the six hearts passively sensitized with anti-DNP and anti-ovalbumin during a period of time up to 10 minutes after antigen challenge corresponded to an average of 150 and 450 fmol of AGEPC, respectively. These estimated amounts of PAF were based upon the assumption that cardiac PAF is AGEPC. Moreover, they probably represented only a rough estimate, since losses of PAF were likely to have occurred during TLC purification. Indeed, we have observed 40-90% recoveries of [ 3 H]AGEPC (New England Nuclear, 50 Ci/mM) after TLC purification, with variations in recoveries occurring between and within TLC plates. Thus, in subsequent studies performed using seven additional anti-DNP-sensitized hearts, trace quantities of [ 3 H] AGEPC were added to each coronary effluent prior to initial lipid extraction and TLC, to serve as an internal standard to assess losses of PAF during purification (Fig.  1) . The amount of [ 3 H]AGEPC added (5000 cpm) was insufficient to affect the platelet release reaction assays and quantification of PAF (Demopoulos et al., 1979) .
Results
Release of PAF during Cardiac Anaphylaxis
Intraortic injection of DNP-BSA into isolated and perfused hearts from seven guinea pigs passively sensitized with guinea pig anti-DNP-BGG resulted in a typical anaphylactic crisis (Fig. 1) . The heart rate ( Fig. la) increased abruptly, reaching a peak within 1 minute after anngenic challenge. A transient increase in ventricular contractile force (Fig. lb) was followed by a prolonged decrease, reaching its nadir 8 minutes after challenge. A prompt and prolonged decrease in coronary flow also occurred (Fig. lc) . Arrhythmias began about 1 minute after antigenic challenge and lasted 7.10 ± 2.68 minutes (mean ± SEM; Fig. la, inset) ; they consisted of idioventricular arrhythmias and conduction defects ranging from partial to complete AV block. In concert with the preceding, both histamine and PAF were released into the coronary effluent during the anaphylactic crisis (Fig. Id) , with maximal PAF release delayed, 
and B: change in rate (panel A) and ventricular contractility (panel B) at the time indicated, compared with the control period preceding antigenic challenge. Inset in panel A ends of shaded bar indicate time of onset and termination of arrhythmias (second and third-degree A-V block and idioventricular rhythms). Panel O changes in average coronary flow rate during 2-minute intervals compared with control period. Panel D: release of histamine and PAF into the coronary effluent during 2-minute intervals following challenge; PAF values have been corrected relative to the recovery of the internal fH]
AGEPC standard during TIC preparation, Le., 68.6 ± 1.6% (mean ± SEW, n = 56). In the 2-minute interval preceding antigen challenge, histamine concentration in the coronary effluent was 3.0 ± 1.0 pmol (±SEM, n == 7); there was no detectable PAF. compared with that of histamine. Histamine release was maximal within 2 minutes after antigen challenge and rapidly declined thereafter, whereas, PAF release, although detectable within 2 minutes, increased to a maximum between 4 and 6 minutes after antigen challenge and declined slowly thereafter. No PAF was released from sensitized hearts prior to antigen challenge or from nonsensitized hearts challenged with antigen. Minimal amounts of histamine were present in the coronary effluents of sensitized hearts prior to antigen challenge (3.0 ±1.0 pmol; mean ± SEM, n = 7).
Effects of Exogenous AGEPC on the Guinea Pig Heart
Because the PAF released during cardiac anaphylaxis appeared by the criteria used to be physicochemically and functionally identical to AGEPC (see Methods), we assessed the possibility that PAF caused some of the concomitant functional changes by evaluating the effects of the administration of exogenous AGEPC in the nonsensitized isolated guinea pig heart. These studies documented that AGEPC reduced the force of contraction, reduced coronary flow, and caused arrhythmias when administered to isolated guinea pig hearts that were perfused at constant pressure. The response to AGEPC was prompt, reached a peak within 2 minutes and was long-lasting (Fig. 2) . AGEPC (10~1 4 to 3 X 10~9 mol) reduced both the force of contraction and the coronary flow rate as a function of dose (Fig. 3) . These effects were not blocked by the cyclooxygenase inhibitor, indomethacin (1 jig/ml; Fig.  3 ), nor by the end-organ SRS-A antagonist FPL 55712 (250 ng/ml; Table 2 ). In contrast to AGEPC, its deacetylated derivative lyso-GEPC caused minimal (less than 10%) decreases in contractile force and coronary flow rate in doses up to 10~8 mol (Figs.  2C and 3) .
AGEPC produced conduction arrhythmias ranging from second degree AV conduction block (Wenckebach phenomenon, 2:1 and 3:1 block) to complete AV dissociation with junctional rhythms. The severity and duration of the conduction arrhythmias increased with the dose of AGEPC (10~1 2 to 3 X 1(T 9 mol; see Table 3 ). AGEPC and lyso-GEPC caused only slight increases in heart rate (10%) which were not dose-related.
In isolated guinea pig hearts perfused at a constant flow, AGEPC (10" ]i to 1(T 8 M) decreased left ventricular contractile force and also increased perfusion pressures as a function of its concentration (Fig. 4) . Reversible conduction arrhythmias similar to those observed when AGEPC was injected into hearts perfused at constant pressure also were observed when AGEPC (10~9 M) was perfused through the hearts at constant flow. At 10~8 M, AGEPC caused irreversible arrhythmias and normal sinus rhythm did not return even after prolonged perfusion with AGEPC-free medium. Since the negative inotropic and arrhythmogenic effects of AGEPC were present also in hearts perfused at constant flow, it is unlikely that the effects of AGEPC were secondary to reduction in coronary flow. On the other hand, the increase in perfusion pressure observed in hearts perfused at constant flow, indicated that AGEPC increased coronary vascular resistance. Because this could have produced regional shunting and ischemia, which may have contributed to arrhythmias and negative inotropism, we assessed the effects of AGEPC in the electrically paced, isolated left atrium and right ventricular papillary muscle of the guinea pig. In these preparations, changes in contractility were totally independent of changes in sinus rate Left ventricular contractile force -43 ± 8 | -44 ± 6 Coronary flow rate -50 ± 7f -60 ± 6 * AGEPC (10"" mol) was administered by bolus intraaortic injection in isolated guinea pig hearts. FPL 55712 (250 ng/ml) was administered by continuous perfusion.
f Percent change from control (±SEM; n = 3-5). and coronary flow. As a function of is concentration, AGEPC (lCT 11 to 10" 5 M) caused a negative inotropic effect in the left atrium (Fig. 5A ) and in the right papillary muscle (Fig. 5B) . Lyso-GEPC caused a minimal (about 5%) decrease in the contractile force of the left atrium at a concentration of 10~5 M (Fig. 5A ).
Discussion
During anaphylaxis in the isolated guinea pig heart, a PAF is released into the coronary effluent which appears to have physicochemical and functional properties similar to AGEPC. AGEPC administered to isolated hearts mimicked many, but not all, of the pathophysiological changes observed during cardiac anaphylaxis. Our findings suggest that release of endogenous cardiac PAF may contribute at least in part to cardiac dysfunction during anaphylaxis in vitro.
In initial experiments (see Methods; Burke et al., 1982b) , we detected the release of PAF also from hearts of guinea pigs sensitized with heterologous antibodies (i.e., rabbit antiovalbumin IgG). Subsequently, we have quantitatively defined the release of PAF from the heart of guinea pigs sensitized with homologous antibodies (i.e., guinea pig anti-DNP Igd). Thus, PAF release is a characteristic feature of cardiac anaphylaxis and is independent of the type of cytotropic antibody.
We have demonstrated that the administration of AGEPC to nonsensitized isolated hearts mimicks some of the functional changes observed during cardiac anaphylaxis. Low doses of AGEPC (1CT 14 to 3 X 10" 9 mol) induced profound and long-lasting decreases in contractility, coronary flow, and slowed AV conduction. In contrast, 10" 8 mol of lyso-GEPC, the deacetylated derivative of AGEPC, which is devoid of any other known biological activity (c.f. Pinckard et al., 1982) , had negligible cardiac effects. Although AGEPC reduced coronary flow and increased coronary vascular resistance, which could have caused shunting and regional ischemia, it is unlikely that the negative inotropic and arrhythmogenic effects of AGEPC were secondary to the • AGEPC injected as an intraaortac bolus into normal isolated hearts perfused at constant pressure, f Minutes (mean ± SEM, n = 4-5).
reduction of coronary flow. Indeed, we found that AGEPC induced a concentration-dependent negative inotropic effect in the left atrium and in the papillary muscle of the right ventricle (see Fig. 5 ). Both preparations were immersed in the perfusing medium, rather than being directly perfused through the coronary vasculature, as in the Langendorff preparation; thus, changes in contractility were independent of coronary flow. It was of no surprise that cardiac contractile responses were relatively independent of coronary flow changes; in fact, we had observed previously that negative inotropic responses to either histamine (Zavecz and Levi, 1978) or sodium arachidonate could coexist with increases in coronary flow. Hence, although we cannot entirely rule out that the reduction in coronary flow caused by AGEPC might in part have contributed to its negative inotropic effects, our experiments indicate that this contribution was minimal.
AGEPC-induced reduction in coronary flow and contractility and slowing of AV conduction were independent of platelet aggregation or release of vasoactive amines from platelets, because they occurred in hearts perfused with platelet-free media. The finding that indomethacin (1 jig/ml, a concentration which effectively blocks cyclooxygenase in the heart; Allan and Levi, 1981) did not block the direct cardiac effects of AGEPC indicates that these effects were not mediated by cyclooxygenase products of arachidonic acid metabolism. This point is important, since AGEPC induces the release of thromboxane in vitro and in vivo (McManus et al., , 1983 , a substance which causes coronary vasoconstriction (Needleman et al., 1977; Terashita et al., 1978; Lewy et al., 1980) . Moreover, recent studies in the perfused rabbit lung have shown that AGEPC-induced pulmonary hypertension and edema are platelet and thromboxane A 2 dependent (Heffner et al., 1983) . In the present study, the negative inotropic and coronary-constricting effects of AGEPC also were not modified by the leukotriene antagonist compound FPL 55712 [250 ng/ml, a concentration which shifts the dose-response curves for the cardiac effects of leukotrienes in the guinea pig heart to the right by 1-2 log units (Burke et al., 1982a) ]. This is important in view of recent evidence that AGEPC releases leukotrienes from isolated, perfused rat lungs (Voelkel et al., 1982) ; and leukotrienes C 4 and D 4 have been shown to cause negative inotropism and coronary constriction in the guinea pig heart (Burke et al., 1982a) .
Our findings raise the question as to whether sufficient PAF was released during cardiac anaphylaxis to account for the observed contractile failure, reduction in coronary flow, and arrhythmias. DNP-BSA-challenged hearts released 5.6 X 10" 13 mol of PAF (assuming that cardiac PAF is identical to AGEPC) during the first 14 minutes after antigen challenge. During this period, the maximum decreases in cardiac contractility and coronary flow were 37% and 28%, respectively, and conduction §1- arrhythmias developed. In comparison, significant decreases in cardiac contractility and coronary flow occurred in normal, unsensitized hearts after bolus administrations of 10~1 3 mol of AGEPC; moreover, 10~n mol of AGEPC caused cardiac arrhythmias and decreases in contractility and flow of severity comparable to those observed during anaphylaxis (Fig. 3) . Since the coronary flow rates decreased during cardiac anaphylaxis to approximately 2-5 ml/2 minutes, the molar concentration of PAF in the coronary effluents would have approximated 1.4-2.0 X 10~u M AGEPC; this concentration of AGEPC administered continuously at constant flow induced significant reductions in left ventricular contractility and increases in coronary perfusion pressures (Fig. 4) . Thus, it would appear that the quantity of AGEPC released from the heart during anaphylaxis was sufficient to cause cardiac dysfunction, although it may not be enough to entirely account for all the changes observed. Furthermore, the amount of detectable PAF released into the cardiac effluent during anaphylaxis may underestimate the total amount of PAF synthesized at the site(s) of action within the myocardium. Since PAF is a phospholipid, significant amounts of newly synthesized PAF could have become tightly bound and retained within the myocardium, possibly in association with its chemoreceptor, thus preventing its release into the coronary effluent.
It should be stressed that several other mediators with cardiac effects similar to AGEPC are also released concurrently during cardiac anaphylaxis. For example, several arachidonic acid metabolites released during cardiac anaphylaxis have negative inotropic effects [e.g., PGF 2o , PGD 2 , and leukotrienes (Anhut et al., 1978; Allan and Levi, 1980; Levi et al., 1982; Burke et al., 1982a) ]. The leukotrienes and thromboxanes are likely contributors to the decreased coronary flow during anaphylaxis (Allan and Levi, 1981) , and histamine is a major cause of the conduction arrhythmias . Thus, the contractile failure and reduced coronary flow would not unexpectedly be due to the combined effects, possibly synergjstic, of these other mediators and AGEPC.
In summary, our results suggest that AGEPC may contribute, at least in part, to the contractile failure, reduced coronary flow, and conduction arrhythmias of cardiac anaphylaxis. Whether inhibition of AGEPC synthesis or pharmacological antagonism of its effects would significantly attenuate these cardiac abnormalities during anaphylaxis is a critical question for future research.
